Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 April 2015
MSD announced that its anti-PD1 immunotherapy pembrolizumab (trade name KEYTRUDA®) has been registered by the Therapeutic Goods Administration (TGA) for the treatment of the most deadly form of skin cancer – advanced metastatic melanoma. Australia is the first country in the world to register KEYTRUDA for the first line treatment of unresectable or metastatic melanoma in adults. This will change the future of treatments for all melanoma patients in Australia.
Associate Professor Georgina Long from Melanoma Institute of Australia (MIA) explained that Australian clinicians and institutes have been involved in the clinical trials of anti-PD1 for over three years.
“We are proud to have been involved in the development of this medicine and that hundreds of Australian patients with advanced melanoma have been treated with pembrolizumab. This drug is being investigated for use in other cancers. It is vital we continue to do research such as this to improve the outcomes for cancer patients.”
MIA and affiliates will continue to lobby on behalf of the Australian community to ensure anti-PD1 is added to the PBS which would make it accessible for all Australians with advanced melanoma without delay.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.